Patent classifications
A61K31/221
High penetration prodrug compositions of retinoids and retinoids-related compounds
The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
High penetration prodrug compositions of retinoids and retinoids-related compounds
The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
Compositions and methods for neuroprotection and treatment of neurodegeneration
Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.
Compositions and methods for neuroprotection and treatment of neurodegeneration
Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.
Compositions and methods for neuroprotection and treatment of neurodegeneration
Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.
PHARMACEUTICAL COMPOSITION COMPRISING PALMITOYLETHANOLAMIDE AND L-ACETYLCARNITINE
It is the object of the present invention a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide for the control of the inflammatory and/or neuropathic pain of various origin. In particular, the present invention relates to a pharmaceutical composition comprising palmitoylethanolamide (PEA and L-acetylcarnitine (LAC), optionally with in addition an antioxidant compound such as a polyphenol, alpha-lipoic acid, and L-acetylcysteine.
PHARMACEUTICAL COMPOSITION COMPRISING PALMITOYLETHANOLAMIDE AND L-ACETYLCARNITINE
It is the object of the present invention a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide for the control of the inflammatory and/or neuropathic pain of various origin. In particular, the present invention relates to a pharmaceutical composition comprising palmitoylethanolamide (PEA and L-acetylcarnitine (LAC), optionally with in addition an antioxidant compound such as a polyphenol, alpha-lipoic acid, and L-acetylcysteine.
OLEYLCYSTEINEAMIDE OR DERIVATIVES THEREOF AND THEIR USE IN THERAPY
The subject-matter of the present application concerns oleylcysteineamide (OCA) and OCA derivatives as active agents and their use in the treatment of inflammatory disorders as well as in treating skin whitening.
Cationic surfactants, in particular ethyl lauroyl arginate LAE, for treating or preventing infections and contaminations with Coronavirus
Disclosed is a method of treatment of surfaces to prevent or treat their contamination with Coronavirus, characterized in that a cationic surfactant of the following formula (1)
##STR00001##
where:
X.sup.− is Br.sup.−, Cl.sup.−, or HSO4.sup.−, a counter ion derived from an organic or inorganic acids, or an anion on the basis of a phenolic compound;
R.sub.1 is a linear alkyl chain from a saturated fatty acid or hydroxy acid from 8 to 14 atoms of carbon bonded to the α-amino acid group through an amidic bond,
R.sub.2 is a linear or branched alkyl chain from 1 to 18 carbon atoms or an aromatic group,
R.sub.3 is
##STR00002##
and n can be from 0 to 4,
is applied to the surface.
Particularly preferred is the use of the cationic surfactant of formula (2) designated as LAE®, which is the ethyl ester of the lauramide of the arginine monohydrochloride.
DIETARY SUPPLEMENT FOR IMPROVING BRAIN PERFORMANCE
Disclosed herein is a dietary supplement containing alpha-glyceryl phosphoryl choline, phosphatidylserine, and an alkalizing agent, and its use in methods of maintaining or improving brain functions, such as mental focus, clarity, long-term memory, short-term memory, analytical reasoning, higher learning, mental processing, mental clarity, creativity, procrastination, willpower, reasoning, mood, retrieval/recall, learning gradient, and reaction time. The supplement can also be used in methods of treating or preventing cognitive dysfunction and dementia.